Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A

Journal of Medicinal Chemistry

Volumn 46, Issue 23, 2003, Pages 4826-4829

  Mai, Antonello ^a   Massa, Silvio ^b   Pezzi, Riccardo ^a   Rotili, Dante ^a   Loidl, Peter ^c   Brosch, Gerald ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

(OXOPROPENYL)PYRROLYLHYDROXYAMIDE; AMIDE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1A; HISTONE DEACETYLASE INHIBITOR; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS;

EID: 0242362600     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034167p     Document Type: Article

References (42)

1. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
2. Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 1999, 9, 40-48.
3. Pazin, M. J.; Kadonaga, J. T. What is up and down with histone deacetylation and transcription? Cell 1997, 89, 325-328.
4. Loidl, P. Histone Acetylation: facts and questions. Chromosoma 1994, 103, 441-449.
5. Davie, J. R. Covalent modifications of histones: expression from chromatin templates. Curr. Opin. Genet. Dev. 1998, 8, 173-178.
6. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature 2000, 403, 41-45.
7. Lin, R. J.; Sternsdorf, T.; Tini, M.; Evans, R. M. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001, 20, 7204-7215.
8. Grignani, F.; De Matteis, S.; Nervi, C.; Tomassoni, L.; Gelmetti, V.; Cioce, M.; Fanelli, M.; Ruthardt, M.; Ferrara, F. F.; Zamir, I.; Seiser, C.; Grignani, F.; Lazar, M. A.; Minucci, S.; Pelicci, P. G. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukemia. Nature 1998, 391, 815-818.
9. Pandolfi, P. P. Transcription therapy for cancer. Oncogene 2001, 20, 3116-3127.
10. Grozinger, C. M.; Schreiber, S. L. Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors. Chem. Biol. 2002, 9, 3-16.
11. Lusser, A.; Brosch, G.; Loidl, A.; Haas, H.; Loidl, P. Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein. Science 1997, 277, 88-91.
12. Massa, S.; Mai, A.; Sbardella, G.; Esposito, M.; Ragno, R.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a New Class of Synthetic Histone Deacetylase Inhibitors. J. Med. Chem. 2001, 44, 2069-2072.
13. Mai, A.; Massa, S.; Ragno, R.; Esposito, M.; Sbardella, G.; Nocca, G.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. Binding Mode Analysis of 3-(4-Benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: A New Synthetic Histone Deacetylase Inhibitor Inducing Histone Hyperacetylation, Growth Inhibition, and Terminal Cell Differentiation. J. Med. Chem. 2002, 45, 1778-1784.
14. Mai, A.; Massa, S.; Ragno, R.; Cerbara, I.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures. J. Med. Chem. 2003, 46, 512-524.
15. Jung, M.; Brosch, G.; Kölle, D.; Scherf, H.; Gerhäuser, C.; Loidl, P. Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation. J. Med. Chem. 1999, 42, 4669-4679.
16. Wittich, S.; Scherf, H.; Xie, C.; Brosch, G.; Loidl, P.; Gerhäuser, C.; Jung, M. Structure-Activity Relationships on Phenylalanine-Containing Inhibitors of Histone Deacetylase: In Vitro Enzyme Inhibition, Induction of Differentiation, and Inhibition of Proliferation in Friend Leukemic Cells. J. Med. Chem. 2002, 45, 3296-3309.
17. Bertos, N. R.; Wang, A. H.; Yang, X.-J. Class II histone deacetylases: Structure, function, and regulation. Biochem. Cell Biol. 2001, 79, 243-252.
18. Fischle, W.; Kiermer, V.; Dequiedt, F.; Verdin, E. The emergency role of class II histone deacetylases. Biochem. Cell Biol. 2001, 79, 337-348.
19. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A. ; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
20. Yang, X.-J.; Seto, E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr. Opin. Genet. Dev. 2003, 13, 143-153.
21. Zhang, C. L.; McKinsey, T. A.; Chang, S.; Antos, C. L.; Hill, J. A.; Olson, E. N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110, 479-488.
22. (a) Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and Specific Inhibition of Mammalian Histone Deacetylase both In Vivo and In Vitro by Trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179, (TSA).
23. (b) Kijima, M.; Yoshida, M.; Suguta, K.; Horinouchi, S.; Beppu, T. Trapoxin, an Antitumor Cyclic Tetra-peptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase. J. Biol. Chem. 1993, 268, 22429-22435, (Trapoxin).
24. (c) Shute, R. E.; Dunlap, B.; Rich, D. H. Analogues of the Cytostatic and Antimitogenic Agents Chlamydocin and HC-Toxin: Synthesis and Biological Activity of Chloromethyl Ketone and Diazomethyl Ketone Functionalized Cyclic Tetrapeptides. J. Med. Chem. 1987, 30, 71-78, (HC-Toxin).
25. (d) Ueda, H.; Nakajima, H.; Hori, Y.; Fujita, T.; Nishimura, M.; Goto, T.; Okuhara, M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activity. J. Antibiot. 1994, 47, 301-310, (FK-228).
26. (e) Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 87-92, (CHAPs).
27. (f) Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3003-3007, (SAHA).
28. Kelly, W. K.; O'Connor, O. A.; Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs 2002, 11, 1695-1713.
29. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
30. Jung, M. Inhibitors of Histone Deacetylase as New Anticancer Agents. Curr. Med. Chem. 2001, 8, 1505-1511.
31. Vigushin, D. M.; Coombes, R. C. Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs 2001, 13, 1-13.
32. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1, 287-299.
33. Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin. Org. Lett. 2001, 3, 4239-4242.
34. Wong, J. C.; Hong, R.; Schreiber, S. L. Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity. J. Am. Chem. Soc. 2003, 125, 5586-5587.
35. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Butcher, R. A.; Schreiber, S. L. Multidimensional Chemical Genetic Analysis of Diversity-Oriented Synthesis-Derived Deacetylase Inhibitors Using Cell-Based Assays. Chem. Biol. 2003, 10, 383-396.
36. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4389-4394.
37. Fumurai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases. Cancer Res. 2002, 62, 4916-4921.
38. 3H] -acetate prelabeled chicken reticulocyte histones (10 μL, 4 mg/mL) and compounds. Reaction was stopped by 1 M HCl/0.4 M acetate (36 μL) and ethyl acetate (800 μL). After centrifugation (10000g, 5 min), an aliquot of the upper phase (600 μL) was counted for radioactivity in liquid scintillation cocktail (3 mL).
39. Brosch, G.; Lusser, A.; Goralik-Schramel, M.; Loidl, P. Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. Biochemistry 1996, 35, 15907-15914.
40. Kölle, D.; Brosch, G.; Lechner, T.; Lusser, A.; Loidl, P. Biochemical methods for analysis of histone deacetylases. Methods 1998, 15, 323-331.
41. Kölle, D.; Brosch, G.; Lechner, T.; Pipal, A.; Helliger, W.; Taplick, J.; Loidl, P. Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Biochemistry 1999, 38, 6769-6773.
42. Brosch, G.; Ransom, R.; Lechner, T.; Walton, J.; Loidl, P. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell 1995, 33, 1941-1950.